{"DataElement":{"publicId":"3536196","version":"1","preferredName":"Patient Immunosuppressive Therapy Clinical Trial Eligibility Criteria Yes No Indicator","preferredDefinition":"the yes/no indicator related to patient eligibility criteria and immunosuppressive therapy as elements of a personal medical history which are necessary to allow an individual to participate in a specific clinical trial.","longName":"3536195v1.0:3506068v1.0","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"3536195","version":"1","preferredName":"Patient Immunosuppressive Therapy Clinical Trial Eligibility Criteria","preferredDefinition":"information relating to patient eligibility criteria and immunosuppressive therapy (therapy used to decrease the body's immune response, such as drugs given to prevent transplant rejection) as elements of a personal medical history which are necessary to allow an individual to participate in a specific clinical trial.","longName":"2233604v1.0:3536193v1.0","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2233604","version":"1","preferredName":"Patient","preferredDefinition":"A person who requires medical care.","longName":"C16960","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Patient","conceptCode":"C16960","definition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F95D94B9-D847-2792-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-13","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-13","modifiedBy":"ONEDATA","dateModified":"2005-06-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3536193","version":"1","preferredName":"Immunosuppressive Therapy Clinical Trial Eligibility Criteria","preferredDefinition":"deliberate suppression of immune system function for experimental or therapeutic purposes.:Elements of a personal medical history which are necessary to allow an individual to participate in a specific clinical trial.","longName":"C15261:C16112","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Immunosuppressive Therapy","conceptCode":"C15261","definition":"deliberate suppression of immune system function for experimental or therapeutic purposes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Clinical Trial Eligibility Criteria","conceptCode":"C16112","definition":"Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C5C0D4AE-1899-2CC8-E040-BB89AD433375","latestVersionIndicator":"Yes","beginDate":"2012-07-26","endDate":null,"createdBy":"LEL","dateCreated":"2012-07-26","modifiedBy":"ONEDATA","dateModified":"2012-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C5C0D4AE-18AA-2CC8-E040-BB89AD433375","latestVersionIndicator":"Yes","beginDate":"2012-07-26","endDate":null,"createdBy":"LEL","dateCreated":"2012-07-26","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3506068","version":"1","preferredName":"Yes No Indicator","preferredDefinition":"The preferred Value Domain to indicate a question with permissible values of yes/no.","longName":"YES_NO_IND","context":"NCI Standards","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"2","maxLength":"3","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"No","valueDescription":"No","ValueMeaning":{"publicId":"3197154","version":"1","preferredName":"No","longName":"3197154","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-55AD-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":"2022.12.28 Alt VM added per ticket request CADSR0001837. aj","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C37A1BEB-75C2-B6C9-E040-BB89AD434179","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"},{"value":"Yes","valueDescription":"Yes","ValueMeaning":{"publicId":"3197153","version":"1","preferredName":"Yes","longName":"3197153v1.00","preferredDefinition":"The affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-558A-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C37A1BEB-75CC-B6C9-E040-BB89AD434179","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"3502157","version":"1","preferredName":"Yes No Indicator Value Domains","preferredDefinition":"Conceptual domain that includes value meanings to be used for Indicator Value Meanings such as Yes, No, Unknown, No Applicable","longName":"YES_NO_IND_VD","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C377DE0C-8C3E-DCA8-E040-BB89AD431B6D","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CURTIST","dateCreated":"2012-06-27","modifiedBy":"CURTIST","dateModified":"2012-06-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2421125","version":"1","preferredName":"Ind-2","preferredDefinition":"A caDSR representation term that is used to indicate a question with permissible values of yes/no","longName":"C38147","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes or No Response","conceptCode":"C38147","definition":"A response or indicator that can have a value of either yes or no.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RETIRED ARCHIVED","registrationStatus":"Retired","id":"0303DF01-F4B4-15EC-E044-0003BA3F9857","latestVersionIndicator":"No","beginDate":"2005-10-18","endDate":"2016-04-27","createdBy":"SHIDED","dateCreated":"2005-10-18","modifiedBy":"TAYLORT","dateModified":"2020-10-03","changeDescription":"10.3.20 TL changed WFS from RETIRED PHASED OUT to RETIRED ARCHIVED. Changed Workflow Status DBW 04-27-2016","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Standard","id":"C37A1BEB-75AE-B6C9-E040-BB89AD434179","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"TSESU","dateModified":"2023-08-16","changeDescription":"8/29/17 tt added CSI per Round 5 finalization task. 3/12/17 jk added Standard reg status; ownership transfered from CTEP to NCI Standards with concurrence of CTEP/Brian Campbell. jk","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008589","version":"2","longName":"Type of Category","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811954","version":"1","longName":"Eligibility Criteria","context":"CTEP"}]},{"publicId":"2961451","version":"1","longName":"Children's Oncology Group (COG)","context":"COG","ClassificationSchemeItems":[{"publicId":"2961452","version":"1","longName":"Statistics and Data Center","context":"COG"}]},{"publicId":"4057943","version":"1","longName":"Disease Site","context":"NRG","ClassificationSchemeItems":[{"publicId":"10000078","version":"1","longName":"GOG-0186H","context":"NRG"},{"publicId":"10000077","version":"1","longName":"GOG-0186H","context":"NRG"},{"publicId":"4104904","version":"1","longName":"GOG-0186H","context":"NRG"}]},{"publicId":"4280691","version":"1","longName":"CRF CDEs","context":"ABTC","ClassificationSchemeItems":[{"publicId":"4280724","version":"1","longName":"Eligibility Checklist","context":"ABTC"}]}],"AlternateNames":[{"name":"SWOG","type":"USED_BY","context":"SWOG"},{"name":"IMSP","type":"OID, SWOG","context":"SWOG"},{"name":"NRG","type":"USED_BY","context":"NRG"},{"name":"3536195v1.0:3506068v1.0","type":"USED_BY","context":"NRG"},{"name":"3536195v1.0:3506068v1.0","type":"USED_BY","context":"CITN"},{"name":"PBTC","type":"USED_BY","context":"PBTC"},{"name":"ABTC","type":"USED_BY","context":"ABTC"},{"name":"Alliance","type":"USED_BY","context":"Alliance"},{"name":"Imsp_Med_IND","type":"OID, COG","context":"COG"},{"name":"COG","type":"USED_BY","context":"COG"},{"name":"IMSP_MED_ELIG_ IND","type":"COG GDE Short Name","context":"COG"},{"name":"IMMUNE_MED_OTHS","type":"COG Form Element","context":"COG"}],"ReferenceDocuments":[{"name":"No active (as defined by requ","type":"Preferred Question Text","description":"No active (as defined by requiring immunosuppressive therapy) or history of clinically significant autoimmune disease (as defined by previously requiring immunosuppressive therapy)","url":null,"context":"CTEP"},{"name":"CRF Text1","type":"Alternate Question Text","description":"Patients who have received prior immunosuppressive therapy within 30 days prior to enrollment.","url":null,"context":"CTEP"},{"name":"CRF Text","type":"Alternate Question Text","description":"Is the patient receiving immunosuppressive therapy including chronic oral steroids (at an equivalent dose of greater than prednisone 5 mg daily)?","url":null,"context":"CTEP"},{"name":"CRF Text 2","type":"Alternate Question Text","description":"Active immunosuppressive therapy, including concurrent systemic immunosuppressive therapy or steroid therapy with more than 7 consecutive days of steroids within the prior 4 weeks.  The use of prednisone or equivalent <0.125 mg/kg/day (absolute maximum of 10 mg/day) as replacement therapy is permitted.  Inhaled corticosteroids are permitted.","url":null,"context":"CTEP"},{"name":"CRF Text 3","type":"Alternate Question Text","description":"Concurrent systemic immunosuppressive therapy or steroid therapy with more than 7 consecutive days of steroids within the last 4 weeks (see protocol for exceptions). The use of prednisone or equivalent <0.125 mg/kg/day (absolute maximum of 10 mg/day) as replacement therapy is permitted. Inhaled corticosteroids are permitted","url":null,"context":"CTEP"},{"name":"CRF Text 4","type":"Alternate Question Text","description":"Immunosuppressive therapy within 30 days prior to initiation of protocol therapy.","url":null,"context":"CTEP"},{"name":"NRG_CRF Text","type":"Alternate Question Text","description":"Has the patient received oral or parenteral corticosteroids within 2 weeks of study entry or who have a clinical requirement for ongoing systemic immunosuppressive therapy?","url":null,"context":"NRG"},{"name":"Immunosuppressive medications received","type":"Alternate Question Text","description":"Has patient received any immunosuppressive medications (excluding intranasal/inhaled corticosteroids, or systemic corticosteroids <= 10 mg/day)?","url":null,"context":"SWOG"},{"name":"CRF Text 6","type":"Alternate Question Text","description":"Has an active autoimmune disease requiring systemic treatment within the past 3 months or a documented history of clinically severe autoimmune disease, or a syndrome that requires systemic steroids or immunosuppressive agents. Patients with vitiligo or resolved childhood asthma/atopy would be an exception to this rule. Patients that require intermittent use of bronchodilators or local steroid injections would not be excluded from the study. Patients with hypothyroidism stable on hormone replacement or Sjorgen's syndrome will not be excluded from the study","url":null,"context":"CTEP"},{"name":"CRF Text 7","type":"Alternate Question Text","description":"Has a diagnosis of immunodeficiency or is receiving therapeutic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment.","url":null,"context":"CTEP"},{"name":"CRF Text 5","type":"Alternate Question Text","description":"Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days before the first dose of trial treatment","url":null,"context":"CTEP"},{"name":"PBTC_Text1","type":"Alternate Question Text","description":"Does the patient have  an active (as defined by requiring immunosuppressive therapy) or history of clinically significant autoimmune disease (as defined by previously requiring immunosuppressive therapy)?","url":null,"context":"PBTC"},{"name":"ABTC 1501 Question","type":"Alternate Question Text","description":"Does the patient have a concurrent condition requiring systemic treatment with either corticosteroids or other immunosuppressive medications within 14 days of study entry?","url":null,"context":"ABTC"},{"name":"ABTC Question","type":"Alternate Question Text","description":"Does the patient have a condition requiring systemic treatment with either corticosteroids or other immunosuppressive medications within 14 days of study entry?","url":null,"context":"ABTC"},{"name":"CRF_Text_8","type":"Alternate Question Text","description":"Will concomitant therapy with any anticancer agents, immunosuppressive agents, or other investigational anticancer therapies be discontinued and avoided for the duration of treatment with copanlisib?","url":null,"context":"CTEP"},{"name":"CRF Text 9","type":"Alternate Question Text","description":"Did the patient have treatment with systemic immunosuppressive medications (including, but not limited to, prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [anti-TNF] agents) within 2 weeks prior to the anticipated Cycle 1, Day 1","url":null,"context":"CTEP"},{"name":"CRF Text 10","type":"Alternate Question Text","description":"Has the patient received systemic immunosuppressive medications (including, but not limited to prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [anti-TNF] agents) within 14 days prior to randomization?","url":null,"context":"CTEP"},{"name":"CRF Text 12","type":"Alternate Question Text","description":"Does the patient have a condition requiring systemic treatment with either corticosteroids (> 10mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration?","url":null,"context":"CTEP"},{"name":"CRF Text11","type":"Alternate Question Text","description":"No current chronic or acute oral steroids.","url":null,"context":"Alliance"},{"name":"NRG_CRF_TEXT1","type":"Alternate Question Text","description":"Does the patient have an active autoimmune disease for which they received systemic treatment in the previous 2 years with corticosteroids, disease modifying agents, or immunosuppressive drugs?","url":null,"context":"NRG"},{"name":"NRG_eCRF_Text","type":"Alternate Question Text","description":"Has the patient had treatment with systemic immunosuppressive medications (including, but not limited to, prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [anti-TNF] agents) within 2 weeks prior to Cycle 1, Day 1?","url":null,"context":"NRG"},{"name":"NRG_eCRF_Text_1","type":"Alternate Question Text","description":"Is the patient receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to study registration?","url":null,"context":"NRG"},{"name":"CRF Text 14","type":"Alternate Question Text","description":"Has the patient been treated with systemic immunosuppressive medications (including but not limited to prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti−tumor necrosis [anti-TNF] factor agents) within 14 days prior to randomization or anticipation of need for systemic immunosuppressive medications during the study?","url":null,"context":"CTEP"},{"name":"CRF Text 13","type":"Alternate Question Text","description":"Has the patient been treated with systemic immunosuppressive medications (including but not limited to prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti−tumor necrosis [anti-TNF] factor agents) within 14 days prior to randomization or anticipation of need for systemic immunosuppressive medications during the study?","url":null,"context":"CTEP"},{"name":"COG CRF Text 1","type":"Alternate Question Text","description":"Is patient on immunosuppressive medications (e.g. tacrolimus, cyclosporine, corticosteriods for reasons other than prevention/treatment of allergic reactions, adrenal replacement therapy, etc.)?","url":null,"context":"COG"},{"name":"NRG_eCRF_Text_2","type":"Alternate Question Text","description":"Is the patient receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to Step 1 registration?","url":null,"context":"NRG"},{"name":"CRF Text15","type":"Alternate Question Text","description":"Concurrent use of immunosuppressive medication including prednisone above 10 mg daily?","url":null,"context":"Alliance"},{"name":"NRG_eCRF_Text_3","type":"Alternate Question Text","description":"Does the patient require current or prior use of immunosuppressive medication within 14 days before enrollment?","url":null,"context":"NRG"},{"name":"CRF Text 19","type":"Alternate Question Text","description":"Does the patient require current or prior use of immunosuppressive medication within 14 days of study registration?","url":null,"context":"NRG"},{"name":"CRF Text16","type":"Alternate Question Text","description":"Condition Requiring Systemic Treatment with Either Corticosteroids or Other Immunosuppressive Medications?","url":null,"context":"Alliance"},{"name":"CRF Text17","type":"Alternate Question Text","description":"Is the patient currently receiving immunosuppressive medication?","url":null,"context":"Alliance"},{"name":"COG CRF Text 02","type":"Alternate Question Text","description":"Is the patient on any other immunosuppressive medications (e.g., cyclosporine, tacrolimus)?","url":null,"context":"COG"},{"name":"NRG_eCRF_Text_5","type":"Alternate Question Text","description":"Has the patient received any other form of immunosuppressive therapy within 7 days of enrollment?","url":null,"context":"NRG"},{"name":"NRG_eCRF_Text_6","type":"Alternate Question Text","description":"Has the patient been treated with systemic immunosuppressive medications (including but not limited to prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis [anti-TNF] factor agents) within 14 days prior to study entry or is it anticipated that the patient will need systemic immunosuppressive medications during the study?","url":null,"context":"NRG"},{"name":"NRG_eCRF_Text_4","type":"Alternate Question Text","description":"Has the patient received systemic steroid therapy or any other form of immunosuppressive therapy within 7 days of enrollment?","url":null,"context":"NRG"},{"name":"COG CRF Text 3","type":"Alternate Question Text","description":"Is patient on chronic immunosuppressive medications (e.g. eg, tacrolimus, cyclosporine, corticosteroids) for reasons other than prevention/treatment of allergic reactions and adrenal replacement therapy?","url":null,"context":"COG"},{"name":"CRF text 18","type":"Alternate Question Text","description":"Prior systemic treatment with either corticosteroids or other immunosuppressive medications?","url":null,"context":"Alliance"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C5C0D4AE-18BB-2CC8-E040-BB89AD433375","latestVersionIndicator":"Yes","beginDate":"2012-07-26","endDate":null,"createdBy":"LEL","dateCreated":"2012-07-26","modifiedBy":"KUMMEROA","dateModified":"2024-01-04","changeDescription":null,"administrativeNotes":"2024.1.4 AQT added per ticket request CADSR0003241. ak","unresolvedIssues":null,"deletedIndicator":"No"}}